Retatrutide vs Tirzepatide: Which Should You Choose for Weight Loss?

If you have been researching the newest medications for weight loss, two names are likely to keep appearing: **tirzepatide** and **retatrutide**.

Tirzepatide has already changed medical weight management. Retatrutide, meanwhile, is an investigational medication that has generated significant attention because early and Phase 3 clinical trial results suggest the potential for even greater average weight loss.

So when comparing **retatrutide vs tirzepatide, which is better?**

The most important distinction in 2026 is simple: **tirzepatide is FDA-approved and available for appropriate patients, while retatrutide remains investigational and has not yet been approved for public use.** Lilly states that retatrutide is currently being studied in Phase 3 trials and should not be obtained outside legitimate clinical research.

That does not make the comparison any less interesting. Retatrutide's newest clinical data suggest that the next generation of metabolic medications could potentially produce levels of weight loss previously associated primarily with bariatric surgery.

## Retatrutide vs Tirzepatide at a Glance

| Feature                                            | Tirzepatide                                        | Retatrutide                                         |

| -------------------------------------------------- | -------------------------------------------------- | --------------------------------------------------- |

| Receptors targeted                                 | GLP-1 + GIP                                        | GLP-1 + GIP + glucagon                              |

| Medication type                                    | Dual receptor agonist                              | Triple receptor agonist                             |

| Injection frequency                                | Once weekly                                        | Once weekly in clinical trials                      |

| FDA-approved for weight management?                | **Yes**                                            | **No — investigational**                            |

| Maximum average weight loss in major obesity trial | About **20.9% at 72 weeks** in SURMOUNT-1          | About **28.3% at 80 weeks** with 12 mg in TRIUMPH-1 |

| Evidence base                                      | Extensive Phase 3 and real-world use               | Phase 3 program ongoing                             |

| Current clinical availability                      | Available by prescription for appropriate patients | Clinical trials only                                |

The percentages above come from separate clinical trials with different populations and study designs, so they **should not be interpreted as a head-to-head comparison**.

## What Is Tirzepatide?

Tirzepatide is a once-weekly medication that activates two metabolic hormone receptors:

* **GLP-1**

* **GIP**

GLP-1 signaling can reduce appetite, increase feelings of fullness, slow gastric emptying and improve glucose regulation. GIP signaling appears to complement these metabolic effects.

Tirzepatide is marketed as **Zepbound for chronic weight management** and as **Mounjaro for type 2 diabetes**.

The FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity or certain adults with overweight and at least one weight-related condition, along with reduced-calorie nutrition and increased physical activity.

It was subsequently FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, making tirzepatide relevant not only to weight reduction but also to certain obesity-related health complications.

## How Effective Is Tirzepatide for Weight Loss?

Tirzepatide has produced some of the largest weight reductions seen with an FDA-approved obesity medication.

In the landmark **SURMOUNT-1 trial**, adults with obesity or overweight without diabetes received tirzepatide or placebo for 72 weeks.

Average body-weight reductions were:

* **15.0%** with 5 mg tirzepatide

* **19.5%** with 10 mg

* **20.9%** with 15 mg

* **3.1%** with placebo

More than half of participants receiving the 15 mg dose lost at least 20% of their starting body weight.

For someone beginning treatment at 250 pounds, a 20% reduction would equal approximately 50 pounds. Individual results can vary substantially.

Tirzepatide has also demonstrated improvements in waist circumference and other cardiometabolic measures in clinical trials.

## What Is Retatrutide?

Retatrutide is the next-generation medication being developed by Eli Lilly.

While tirzepatide activates two hormone receptors, retatrutide activates three:

* **GLP-1**

* **GIP**

* **Glucagon**

This is why retatrutide is often called a **triple agonist** or **triple hormone receptor agonist**.

The additional glucagon receptor activity is one of the key differences between retatrutide and tirzepatide.

GLP-1 and GIP signaling primarily affect appetite, satiety and glucose metabolism. Researchers believe the glucagon component may add additional effects on energy balance and metabolism.

Importantly, however, **retatrutide remains an investigational drug as of September 2026**. It has not received FDA approval and is not commercially available as an FDA-approved medication.

## How Much Weight Can You Lose With Retatrutide?

This is where retatrutide has generated so much interest.

Earlier Phase 2 research published in the *New England Journal of Medicine* found average weight loss as high as **24.2% after 48 weeks** in participants receiving the highest studied dose.

The Phase 3 results have been even more noteworthy.

In Lilly's **TRIUMPH-1 Phase 3 trial**, participants without diabetes who received 12 mg retatrutide experienced an average:

**28.3% reduction in body weight at 80 weeks.**

Participants with a baseline BMI of at least 35 who entered a study extension achieved average weight loss of approximately **30.3% at 104 weeks**.

At the lower 4 mg dose, average weight loss was still approximately **19.0% at 80 weeks**.

Phase 3 trials involving patients with diabetes and cardiovascular disease have also reported substantial weight reductions. In TRIUMPH-2, participants with overweight or obesity and type 2 diabetes lost up to an average of **20.8%**, while participants in TRIUMPH-3 with severe obesity and established cardiovascular disease lost up to **22.6%** at 80 weeks.

These results are extremely promising, but they should still be interpreted cautiously until the complete Phase 3 program is published and regulatory review is completed.

## Is Retatrutide Better Than Tirzepatide for Weight Loss?

Based strictly on the magnitude of weight loss reported in separate clinical trials, **retatrutide currently appears capable of producing greater average weight loss than tirzepatide**.

However, this does **not** prove that retatrutide is superior.

There has not yet been a definitive large-scale head-to-head trial showing that retatrutide is better than tirzepatide in otherwise comparable patients.

Comparing results across independent trials has several limitations, including differences in:

* Patient populations

* Starting BMI

* Treatment duration

* Dose escalation

* Lifestyle interventions

* Trial design

* Treatment discontinuation

* Statistical methods

What we can say is that retatrutide's Phase 3 results are among the strongest reported for a medical obesity treatment to date.

## Retatrutide vs Tirzepatide for Metabolic Health

Weight loss is only part of the reason these medications are being studied.

Obesity frequently occurs alongside conditions such as:

* Insulin resistance

* Type 2 diabetes

* High blood pressure

* Abnormal cholesterol and triglycerides

* Fatty liver disease

* Obstructive sleep apnea

* Cardiovascular disease

Tirzepatide already has an extensive clinical evidence base for glucose control and weight management, and clinical trials have shown improvement in multiple cardiometabolic measures.

Retatrutide is being studied for an even broader range of metabolic and obesity-related conditions, including type 2 diabetes, cardiovascular and renal outcomes, obstructive sleep apnea and metabolic dysfunction-associated steatotic liver disease.

Its Phase 3 TRIUMPH-2 trial also reported significant improvements in both body weight and A1C in patients with type 2 diabetes.

## Retatrutide vs Tirzepatide Side Effects

Both medications affect incretin signaling, so their most common side effects are similar.

### Common Tirzepatide Side Effects

Common adverse effects can include:

* Nausea

* Diarrhea

* Vomiting

* Constipation

* Abdominal discomfort

* Indigestion

* Fatigue

* Injection-site reactions

Gastrointestinal symptoms are particularly common during dose escalation and frequently improve over time.

Tirzepatide also carries important warnings and is not appropriate for every patient. A healthcare professional should review personal and family medical history, medications and potential contraindications before treatment.

### Common Retatrutide Side Effects

Retatrutide's Phase 3 safety profile has also been dominated by gastrointestinal symptoms.

In TRIUMPH-1, nausea occurred in approximately 29% to 42% of participants receiving retatrutide depending on dose. Diarrhea, constipation and vomiting were also common. Treatment discontinuation because of adverse events ranged from approximately 4% to 11% across retatrutide groups.

Earlier Phase 2 research also observed dose-related increases in heart rate that peaked during treatment and subsequently declined.

Because retatrutide is still investigational, its complete long-term risk profile has not yet been established.

## Tirzepatide vs Retatrutide: Which Should You Choose?

For patients seeking medical weight-loss treatment **today**, the answer is generally much clearer than the headlines may suggest.

### Tirzepatide may make sense for someone who:

* Meets medical criteria for prescription weight management

* Wants an FDA-approved treatment

* Wants a medication with extensive Phase 3 clinical data

* Needs treatment now rather than waiting for future drug approval

* Can safely use a GLP-1/GIP medication after medical evaluation

### Retatrutide may eventually become an option for someone who:

* Needs greater weight reduction than current medications can provide

* Has obesity complicated by significant metabolic disease

* Does not achieve adequate results with existing therapies

* Can participate in an appropriate clinical trial

* May be a candidate if and when the medication receives FDA approval

At this point, **retatrutide should not be viewed as a commercially available alternative to tirzepatide**.

Lilly specifically states that retatrutide has not been approved by any regulatory agency and is available only through its clinical trials. The company has also warned that products sold online claiming to contain retatrutide may contain incorrect ingredients, contaminants or inaccurate amounts of active ingredient.

## Should You Switch From Tirzepatide to Retatrutide?

Not outside an appropriately conducted clinical trial.

Someone doing well on tirzepatide should not assume that switching to an unapproved product marketed as retatrutide will automatically produce better results.

The 28% weight-loss figures circulating online came from controlled clinical research using a pharmaceutical investigational product with standardized manufacturing, carefully designed dose escalation, patient screening and ongoing safety monitoring.

That is very different from purchasing an unapproved product online.

Until retatrutide completes the regulatory process, tirzepatide remains the more established medical option.

## What About Muscle Loss With Retatrutide or Tirzepatide?

Any substantial weight loss can include both fat mass and lean mass.

For patients using medical weight-loss therapy, preserving muscle should remain an important part of the treatment strategy.

Depending on the individual, a physician-supervised program may include:

* Adequate dietary protein

* Resistance training

* Regular physical activity

* Appropriate calorie targets

* Monitoring the rate of weight loss

* Periodic evaluation of body composition

* Adjustment of treatment when weight loss becomes excessively rapid

The goal should not simply be to make the scale move as quickly as possible. The goal is to improve body composition and long-term metabolic health.

## The Bottom Line: Retatrutide vs Tirzepatide

**Tirzepatide is currently the more practical choice because it is FDA-approved, widely studied and available by prescription for appropriately selected patients.**

**Retatrutide may eventually become the more powerful weight-loss medication**, and its Phase 3 results are extremely impressive. Average weight reduction reached 28.3% in the highest-dose TRIUMPH-1 group compared with approximately 20.9% in the highest-dose tirzepatide group in SURMOUNT-1. But these numbers come from separate trials and cannot establish direct superiority.

For now:

**Tirzepatide = proven, FDA-approved and clinically available.**

**Retatrutide = potentially more powerful, but still investigational.**

If you are considering medical weight-loss treatment, the best medication is not necessarily the drug producing the largest percentage on a clinical trial graph. Your health history, current weight, metabolic conditions, previous treatments, medications, side-effect tolerance and long-term goals all matter.

### Interested in Medical Weight Loss?

Our medical team can evaluate your health history, weight-loss goals and laboratory results to determine whether an **FDA-approved medical weight-loss treatment such as tirzepatide** may be appropriate for you.

**Schedule a consultation today to develop a physician-guided weight-loss plan built around your individual goals and metabolic health.**

---

## Frequently Asked Questions

### Is retatrutide stronger than tirzepatide?

Retatrutide has produced greater average weight loss in some Phase 3 trials than tirzepatide produced in its major obesity trials. However, the medications have not yet been definitively compared head-to-head, so it cannot be concluded from separate studies alone that retatrutide is superior.

### How much weight can you lose on retatrutide?

In Lilly's TRIUMPH-1 Phase 3 trial, participants receiving 12 mg retatrutide lost an average of approximately 28.3% of their body weight at 80 weeks. Individual results vary.

### How much weight can you lose on tirzepatide?

In SURMOUNT-1, participants receiving 15 mg tirzepatide lost an average of approximately 20.9% of their starting weight after 72 weeks.

### Is retatrutide FDA-approved?

No. As of September 2026, retatrutide remains investigational and has not been approved by the FDA or another regulatory agency for public use.

### Is tirzepatide FDA-approved for weight loss?

Yes. Tirzepatide is FDA-approved under the brand name Zepbound for chronic weight management in qualifying adults.

### Does retatrutide burn more fat than tirzepatide?

Retatrutide activates the GLP-1, GIP and glucagon receptors, whereas tirzepatide activates GLP-1 and GIP receptors. Retatrutide has produced larger average reductions in body weight in separate clinical trials, but direct comparative evidence is still needed before concluding that it causes greater fat loss than tirzepatide.

### Can I buy retatrutide now?

There is currently no FDA-approved retatrutide product available for public use. Lilly states that retatrutide is available only through its clinical trials and warns against products marketed elsewhere as retatrutide.

### Which is better, retatrutide or tirzepatide?

For someone seeking treatment now, tirzepatide has the major advantage of FDA approval, established clinical data and legitimate prescription availability. Retatrutide is highly promising but remains an investigational medication.

---

**Medical Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Prescription weight-management medications are not appropriate for everyone and should be used only after evaluation by a qualified healthcare professional.